An emerging role for the miR-26 family in cardiovascular disease

Abstract

In response to acute myocardial infarction (MI), a complex series of cellular and molecular signaling events orchestrate the myocardial remodeling that ensues weeks to months after injury. Clinical, epidemiological, and pathological studies demonstrate that inadequate or impaired angiogenesis after myocardial injury is often associated with decreased left ventricular (LV) function and clinical outcomes. The microRNA family, miR-26, plays diverse roles in regulating key aspects of cellular growth, development, and activation. Recent evidence supports a central role for the miR-26 family in cardiovascular disease by controlling critical signaling pathways, such as BMP/SMAD1 signaling, and targets relevant to endothelial cell growth, angiogenesis, and LV function post-MI. Emerging studies of the miR-26 family in other cell types including vascular smooth muscle cells, cardiac fibroblasts, and cardiomyocytes suggest that miR-26 may bear important implications for a range of cardiovascular repair mechanisms. This review examines the current knowledge of the miR-26 family’s role in key cell types that critically control cardiovascular disease under pathological and physiological stimuli

Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension

“…The above mentioned studies and others defining roles of miR-26 on other aspects of cardiovascular biology such as angiogenesis, post-MI LV function, myocardial fibrosis and atrial fibrillation, suggest that miR-26 may bear important implications for a range of cardiovascular repair mechanisms (28). Our study is the first to connect miR-26b with left ventricular hypertrophy in humans.…”

MicroRNA: A new therapeutic strategy for cardiovascular diseases

“…An emerging role of miRNA-26 family and their implications for different cell types during cardiovascular disease condition was reviewed recently [38]. The miRNA-29 family is another important miRNA that acts as a negative regulator of gene expression by targeting the mRNAs that encode proteins involved in fibrosis, including multiple collagens, fibrillins, and elastin.…”

MicroRNA-26a: An Emerging Regulator of Renal Biology and Disease

“…There are two different nucleotides between the mature sequences of miR-26a and miR-26b, whereas miR-26a-1 and miR-26a-2 have fully identical sequences arising from the 5’ arm of the respective precursors [40]. Plenty of publications reported that miR-26a plays an important role in various diseases [41-43], and most of them focused on cancer or cancer-related diseases, including colorectal, breast, ovarian, and gastric cancers [42, 44-47].…”

“…Additionally, miR-26a functions in cardiovascular diseases by controlling multiple signaling pathways related to angiogenesis, endothelial cell growth, and left ventricle function after myocardial infarction. Analysis of miR-26 family members in different types of cardiac cells [52-54], including endothelial cells, vascular smooth muscle cells, cardiomyocytes, and cardiac fibroblasts, has shown that miR-26 may have important functions in various cardiovascular repair mechanisms [55, 56]. Intriguingly, miR-26a has was also been found to negatively regulate glycogen synthase kinase (GSK) 3β expression, thereby altering Wnt signaling by modulating the levels of β-catenin and its downstream target C/EBPα during osteogenesis differentiation [57, 58].…”